I-SPY2 'Graduates' Neratinib; Puma Details Efficacy, Safety Insights in HER2-Positive Breast Cancer | GenomeWeb

At the American Association for Cancer Research annual meeting this week, researchers involved in the adaptive design I-SPY2 trial reported detailed results showing that Puma Biotechnology's neratinib combined with a chemotherapy regimen had a 79 percent statistical probability of being a superior neoadjuvant treatment over standard chemo in a 300-patient study of hormone receptor-negative, HER2-positive patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.